Tyme Technologies (NASDAQ:TYME) posted its quarterly earnings results on Monday. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08), MarketWatch Earnings reports.
Shares of NASDAQ TYME opened at $3.11 on Tuesday. The company has a market capitalization of $288.93 million, a P/E ratio of -14.81 and a beta of 0.32. Tyme Technologies has a 1 year low of $1.93 and a 1 year high of $4.64.
TYME has been the topic of a number of research analyst reports. BidaskClub upgraded shares of Tyme Technologies from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 30th. HC Wainwright set a $10.00 price objective on shares of Tyme Technologies and gave the company a “buy” rating in a report on Friday, January 18th. Finally, Zacks Investment Research lowered shares of Tyme Technologies from a “buy” rating to a “hold” rating in a report on Thursday, January 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. Tyme Technologies has an average rating of “Hold” and an average price target of $7.58.
About Tyme Technologies
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Read More: How to read a candlestick chart
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.